安罗替尼联合依托泊苷加顺铂治疗广泛期小细胞肺癌的临床观察

目的　分析安罗替尼联合依托泊苷加顺铂治疗广泛期小细胞肺癌的临床效果及安全性。方法　选取2017年1月至2019年7月威海市中心医院收治的102例广泛期小细胞肺癌患者作为本次研究对象，并按照随机数字表法分为联合组（51例）与对照组（51例）。联合组男性30例、女性21例；年龄（60.36±6.33）岁。对照组男性29例、女性22例；年龄（60.85±6.69）岁。对照组给予依托泊苷加顺铂治疗，联合组在对照组治疗基础上加用安罗替尼治疗。分析比较两组患者临床疗效、1、2年生存率、无进展生存时间（PFS）、不良反应以及治疗后Karnofsky功能状况（KPS）评分。计量资料采用两独立样本t检验，计数资料采用四格表χ²检验。结果　联合组临床客观缓解率、疾病控制率均高于对照组［74.51%（38/51）比54.90%（28/51），88.24%（45/51）比70.59%（36/51），均P<0.05］。联合组患者治疗6个周期的KPS评分明显高于对照组［（83.36±17.41）分比（73.25±13.20）分］（P<0.05）。联合组与对照组不良反应发生率比较差异无统计学意义（P>0.05）。联合组患者1年、2年生存率均显高于对照组［62.75%（32/51）比43.14%（22/51），49.02%（25/51）比29.41%（15/51），均P<0.05］。联合组患者PFS为9.8个月（95%CI：7.7～11.6个月），对照组患者PFS为7.2个月（95%CI：4.6～9.8个月），两组PFS比较差异有统计学意义（P<0.05）。结论　安罗替尼联合依托泊苷加顺铂治疗广泛期小细胞肺癌的临床效果更好，能够有效延长1、2年生存率与PFS，同时一定程度上提高患者的健康状况，不良反应少，值得临床应用。

Clinical observation of anlotinib combined with etoposide and cisplatin in the treatment of extensive-stage small cell lung cancer

Objective　To analyze the clinical efficacy and safety of anlotinib combined with etoposide and cisplatin in the treatment of extensive-stage small cell lung cancer. Methods　A total of 102 patients with extensive-stage small cell lung cancer who were admitted to Weihai Central Hospital from January 2017 to July 2019 were selected as the research subjects, and they were divided into a combination group (51 cases) and a control group (51 cases) by the random number table. There were 30 males and 21 females in the combination group, aged (60.36±6.33) years; there were 29 males and 22 females in the control group, aged (60.85±6.69) years. The control group was treated with etoposide plus cisplatin, and the combination group was additionally treated with anlotinib based on the treatment of the control group. The clinical efficacy, 1- and 2-year survival rates, progression-free survival (PFS), adverse reactions, and Karnofsky Performance Status (KPS) score after treatment were compared between the two groups. Two independent samples t-test was used for the measurement data, and four-grid table χ² test was used for the count data. Results　The clinical objective response rate and disease control rate of the combination group were higher than those of the control group 74.51% (38/51) vs. 54.90% (28/51), 88.24% (45/51) vs. 70.59% (36/51); both P<0.05]. The KPS score of the combination group after 6 cycles of treatment was significantly higher than that of the control group (83.36±17.41) vs. (73.25±13.20), P<0.05]. The incidence of adverse reactions between the combination group and the control group was no significantly different (P>0.05). The 1- and 2-year survival rates of the combination group were significantly higher than those of the control group 62.75% (32/51) vs. 43.14% (22/51), 49.02% (25/51) vs. 29.41% (15/51); both P<0.05]. The PFS of the combined group was 9.8 months (95%CI: 7.7-11.6 months), and the PFS of the control group was 7.2 months (95%CI: 4.6-9.8 months), with a statistically significant difference between the two groups (P<0.05). Conclusion　Anlotinib combined with etoposide and cisplatin has better clinical effect in the treatment of extensive-stage small cell lung cancer, can effectively prolong the 1- and 2-year survival rates and PFS, and improve the patients' health status, with few adverse reactions, which is worthwhile clinical application.